Alnylam Pharmaceuticals (ALNY) Equity Income: 2009-2012
Historic Equity Income for Alnylam Pharmaceuticals (ALNY) over the last 4 years, with Dec 2012 value amounting to -$881,000.
- Alnylam Pharmaceuticals' Equity Income rose 7.65% to -$881,000 in Q4 2012 from the same period last year, while for Dec 2012 it was -$4.5 million, marking a year-over-year decrease of 29.02%. This contributed to the annual value of -$4.5 million for FY2012, which is 29.02% down from last year.
- Latest data reveals that Alnylam Pharmaceuticals reported Equity Income of -$881,000 as of Q4 2012, which was up 45.38% from -$1.6 million recorded in Q3 2012.
- Alnylam Pharmaceuticals' 5-year Equity Income high stood at $7.9 million for Q3 2009, and its period low was -$13.1 million during Q1 2009.
- In the last 3 years, Alnylam Pharmaceuticals' Equity Income had a median value of -$1.0 million in 2011 and averaged -$1.3 million.
- Within the past 5 years, the most significant YoY rise in Alnylam Pharmaceuticals' Equity Income was 87.93% (2010), while the steepest drop was 380.27% (2010).
- Alnylam Pharmaceuticals' Equity Income (Quarterly) stood at -$1.5 million in 2009, then skyrocketed by 38.44% to -$916,000 in 2010, then fell by 4.15% to -$954,000 in 2011, then grew by 7.65% to -$881,000 in 2012.
- Its Equity Income was -$881,000 in Q4 2012, compared to -$1.6 million in Q3 2012 and -$1.1 million in Q2 2012.